The reduction in the price of a key Aids drug, Stocrin, is expected to put pressure on other global multinationals to reduce their medicine prices. UNAids says further reductions are essential to achieving universal access to the life-saving drugs by 2010. The price cut, which was announced recently on the fifth anniversary of the pharmaceutical company Merck Sharp & Dohme's worldwide HIV/Aids pricing policy, will see the price of Stocrin fall by 20 per cent.